Fig. 1 · Structure

Documents & Downloads

Actinomycin D

Cat. No. A13239 CAS 50-76-0
Actinomycin D is a metabolite isolated from Streptomyces parvulus that binds to the GpC steps of DNA. The compound acts as an antibiotic and is more effective against gram-positive bacteria than gram negative bacteria.

In Stock

Publications for Actinomycin D

10 publications citing this product

  1. Wenjia Xia, .et al. , J RADIAT RES APPL SC, 2026, 19: 102504
  2. Jiayuan Hu, .et al. , Cancer Metab, 2025, Jun 18;13(1):32 PMID: 40533864
  3. Danjun Wang, .et al. , Applied Biological Chemistry, 2025, 68: 24
  4. Hongbo Liu, .et al. , Cancer Biol Ther, 2025, Dec;26(1):2479926 PMID: 40176374
  5. Lixia Wu, .et al. , J Transl Med, 2025, Apr 1;23(1):385 PMID: 40170133
  6. Akane Ogawa, .et al. , Mol Cell, 2025, Mar 6;85(5):894-912 PMID: 39909041
  7. Ruo-Yang Chen, .et al. , International Immunopharmacology, 2025, 147: 113920 PMID: 39799734
  8. Zegui N, .et al. , Cancer Research, 2022, FEBRUARY 22 PMID: 35502544
  9. Lina Gu, .et al. , Molecular Cancer, 2022, 21:217 PMID: 36514094
  10. Chauhan D, .et al. , Cell Rep, 2018, Nov 27;25(9):2354-2368.e5 PMID: 30485805

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Actinomycin D inhibits RNA polymerase II elongation in a sequence-dependent manner. In a reconstituted yeast system, it induced pauses near a downstream GpC site and reduced run-off transcription; a C-to-A mutation in the TGCA motif removed the characteristic inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Actinomycin D Research Summary

This section summarizes 2 in vitro studies of Actinomycin D from 2 published references.

Actinomycin D In Vitro Studies

Actinomycin D produced a model-dependent cell-death response in ependymoma cultures. After 48 h, 5 nM yielded more author-classified apoptosis than 100 nM in EP1NS cells, while SJ-BT57 cells responded similarly at both concentrations. The Annexin V/7AAD endpoint can include necrotic cells. [2]

Sequence-dependent inhibition of RNA polymerase II elongation

Biochemical assay · Reconstituted Saccharomyces cerevisiae Pol II elongation complexes on defined DNA/RNA scaffolds, with GC-rich EGFR-derived and GC-less controls. [1]

Actinomycin D reduced run-off transcription and induced discrete pauses near a downstream GpC site. A C-to-A change in TGCA removed the characteristic inhibition. This is a cell-free elongation endpoint, not a cellular potency or direct enzyme-binding IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Polymerase bypass of the ACTD blockage after 90 minFraction bypassing <20% at 1 μM and 2 μM ACTD[1]
Sequence dependence of transcription pausingQualitative control result Little effect on GC-less control; C-to-A mutation in TGCA abolished inhibition at n−5, n−2 and n−1.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0, 0.2, 0.5, 1.0 and 2.0 μM in the full-bubble dose/time assay; 2 μM in the tailed-scaffold control assay.
Exposure duration
Full-bubble complexes preincubated with ACTD for 30 min at room temperature; transcription sampled at 1, 3, 10, 30 and 90 min. Tailed-scaffold control examined at 20 s, 1, 3 and 10 min.
Method
Reconstituted transcription; fluorescent RNA products resolved by sequencing gel and quantified.
Co-treatment
No second drug. NTP concentrations of 0.01 or 1.0 mM were compared in the sequence-control experiment.
Reported limits
ACTD supplier, lot, solvent and purity were not identified in the inspected main-text assay description; supplementary PDF was acquired but not read.
Methods and source locations

Compound reported in the paper: Actinomycin D; Compound label in the paper: ACTD

Supports parent-compound transcription mechanism in a reconstituted system; no Adooq supplier or lot validation.

Results: ACTD induces sequence-specific Pol II stalling in a reconstituted in vitro transcription system; Fig. 1b–e; Methods: In vitro transcription assay and Protein expression and purification

Polymerase bypass of the ACTD blockage after 90 min: Gel-based RNA product quantification; Fig. 1d reports mean and s.d., n = 3 independent biological repeats. Operator and threshold are reported in the Results; no exact curve decimals inferred. — Fig. 1c–d and first Results subsection

Sequence dependence of transcription pausing: Matched transcription scaffolds; images representative of three independent experiments. — Fig. 1b,e and first Results subsection

Low- versus high-concentration cell-death response in ependymoma

Cell-based study · EP1NS (ST-EPN-RELA) and SJ-BT57 (PF-EPN-A) ependymoma cells, with DMSO controls. [2]

After 48 h, the lower tested concentration produced more author-classified apoptosis in EP1NS than the higher concentration, whereas SJ-BT57 responses were similar. Annexin V/7AAD double-positive events may include necrotic cells; the endpoint does not establish exclusively apoptotic death or a universal inverse dose response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Author-classified apoptotic cells in EP1NSPercentage of cells 5 nM: 44%, SD: ±3%; 100 nM: 21%, SD: ±6%[2]
Author-classified apoptotic cells in SJ-BT57Percentage of cells 5 nM: 50%, SD: ±3%; 100 nM: 45%, SD: ±4%[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 nM and 100 nM
Exposure duration
48 h
Method
Annexin V/7AAD flow cytometry; matched DMSO control panels shown.
Vehicle
DMSO control; final DMSO concentration not specified in the inspected FACS description.
Co-treatment
Actinomycin-D alone; Nutlin-3 experiments were separate and are not adopted.
Reported limits
Replicate count underlying the caption SD is not specified in the inspected FACS method or Fig. 3 caption. Drug lot and purity not specified there.
Methods and source locations

Compound reported in the paper: Actinomycin D; Compound label in the paper: Actinomycin-D

Cell-line results for parent Actinomycin D; not supplier-specific potency, clinical efficacy or validation of an Adooq lot.

Results: apoptosis response to Actinomycin-D; Fig. 3 and caption; Methods: Flow cytometrie (FACS); Discussion: Annexin V/7AAD interpretation

Author-classified apoptotic cells in EP1NS: Annexin V/7AAD flow cytometry after 48 h. Values and SD transcribed from caption, not inferred from scatter plots. — Fig. 3 left panel and caption; FACS methods; corresponding Results

Author-classified apoptotic cells in SJ-BT57: Annexin V/7AAD flow cytometry after 48 h. Values and SD transcribed from caption; n not specified in inspected location. — Fig. 3 right panel and caption; FACS methods; corresponding Results

Specifications

Manufacturer Adooq Bioscience
CAS Number 50-76-0
Formula C62H86N12O16
Molecular Weight 1255.4
SMILES
CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (72.48 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Actinomycin D Research References

  1. [1] Zhao W, Zhu L, Liu Y, et al. Stepwise transcription stalling by the anti-cancer drug Actinomycin D and insights into short tandem repeat transcription inhibition. Nature communications (2026). PMID: 41833943 DOI: 10.1038/s41467-026-70612-y Source material
  2. [2] Tzaridis T, Milde T, Pajtler KW, et al. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. Oncotarget (2016). PMID: 27556362 DOI: 10.18632/oncotarget.11452 Source material

Publications

10 publications citing this product

  1. Wenjia Xia, .et al. , J RADIAT RES APPL SC, 2026, 19: 102504
  2. Jiayuan Hu, .et al. , Cancer Metab, 2025, Jun 18;13(1):32 PMID: 40533864
  3. Danjun Wang, .et al. , Applied Biological Chemistry, 2025, 68: 24
  4. Hongbo Liu, .et al. , Cancer Biol Ther, 2025, Dec;26(1):2479926 PMID: 40176374
  5. Lixia Wu, .et al. , J Transl Med, 2025, Apr 1;23(1):385 PMID: 40170133
  6. Akane Ogawa, .et al. , Mol Cell, 2025, Mar 6;85(5):894-912 PMID: 39909041
  7. Ruo-Yang Chen, .et al. , International Immunopharmacology, 2025, 147: 113920 PMID: 39799734
  8. Zegui N, .et al. , Cancer Research, 2022, FEBRUARY 22 PMID: 35502544
  9. Lina Gu, .et al. , Molecular Cancer, 2022, 21:217 PMID: 36514094
  10. Chauhan D, .et al. , Cell Rep, 2018, Nov 27;25(9):2354-2368.e5 PMID: 30485805

Added to your cart

View Cart Checkout
Loading...